Puma Biotech (PBYI) Reports Q1 EPS of $0.10, provides guidance

Puma Biotech (NASDAQ: PBYI) reported Q1 EPS of $0.10. Revenue for the quarter came in at $46 million versus the consensus estimate of $47.5 million.

GUIDANCE:

Puma Biotech sees Q2 2025 revenue of $48-50 million, versus the consensus of $52.75 million.

Puma Biotech sees FY2025 revenue of $192-198 million, versus the consensus of $218.2 million.

For earnings history and earnings-related data on Puma Biotech (PBYI) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Deutsche Bank Reiterates Buy Rating on Haypp Group AB (HAYPP:SS)
• Primoris cuts 2026 outlook on renewables cost overruns, COO exits